These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 24760272

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
    Rönnau CGH, Fussek S, Smit FP, Aalders TW, van Hooij O, Pinto PMC, Burchardt M, Schalken JA, Verhaegh GW.
    World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
    [Abstract] [Full Text] [Related]

  • 3. Investigating miR-6880-5p in extracellular vesicle from plasma as a prognostic biomarker in endocrine therapy-treated castration-resistant prostate cancer.
    Lee J, Hong J, Kim JW, Lim S, Choi SC, Gim JA, Kang SG, Noh TI, Park KH.
    BMC Cancer; 2024 Jul 29; 24(1):909. PubMed ID: 39075471
    [Abstract] [Full Text] [Related]

  • 4. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
    Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L.
    Eur Urol; 2015 Jan 29; 67(1):33-41. PubMed ID: 25129854
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
    Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M, Naya Y, Ichikawa T, Seki N.
    Br J Cancer; 2015 Sep 29; 113(7):1055-65. PubMed ID: 26325107
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Tinay I, Tan M, Gui B, Werner L, Kibel AS, Jia L.
    Prostate; 2018 Sep 29; 78(12):927-937. PubMed ID: 29748958
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
    Barros-Silva D, Costa-Pinheiro P, Duarte H, Sousa EJ, Evangelista AF, Graça I, Carneiro I, Martins AT, Oliveira J, Carvalho AL, Marques MM, Henrique R, Jerónimo C.
    Cell Death Dis; 2018 Feb 07; 9(2):167. PubMed ID: 29415999
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
    Pimenta RC, Viana NI, Amaral GQ, Park R, Morais DR, Pontes J, Guimaraes VR, Camargo JA, Leite KR, Nahas WC, Srougi M, Reis ST.
    Tumour Biol; 2018 Nov 07; 40(11):1010428318803011. PubMed ID: 30400755
    [Abstract] [Full Text] [Related]

  • 12. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.
    Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T, Maitland NJ.
    Eur Urol; 2015 Jan 07; 67(1):7-10. PubMed ID: 25234358
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
    Jiao L, Deng Z, Xu C, Yu Y, Li Y, Yang C, Chen J, Liu Z, Huang G, Li LC, Sun Y.
    J Cell Physiol; 2014 Jul 07; 229(7):834-44. PubMed ID: 24243035
    [Abstract] [Full Text] [Related]

  • 17. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.
    Br J Cancer; 2017 Jul 25; 117(3):409-420. PubMed ID: 28641312
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
    Benoist GE, van Oort IM, Boerrigter E, Verhaegh GW, van Hooij O, Groen L, Smit F, de Mol P, Hamberg P, Dezentjé VO, Mehra N, Gerritsen W, Somford DM, van Erp NPH, Schalken JA.
    Clin Chem; 2020 Jun 01; 66(6):842-851. PubMed ID: 32408351
    [Abstract] [Full Text] [Related]

  • 19. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.
    Zhu J, Wang S, Zhang W, Qiu J, Shan Y, Yang D, Shen B.
    Oncotarget; 2015 Dec 22; 6(41):43819-30. PubMed ID: 26540468
    [Abstract] [Full Text] [Related]

  • 20. Role of MicroRNA-21 in Prostate Cancer Progression and Metastasis: Molecular Mechanisms to Therapeutic Targets.
    Singh VK, Rajak N, Singh Y, Singh AK, Giri R, Garg N.
    Ann Surg Oncol; 2024 Jul 22; 31(7):4795-4808. PubMed ID: 38758485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.